BGOG-ov62/N-Plus

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

Open
Trial drug
Niraparib
Grade
High grade
Prior lines
Frontline
Biomarkers
HRD
Histology
Serous, Endometrioid Clear-cell
Phase
II

Treatment

This study consists of two different treatment options:

  • Arm A: 3 cycles carboplatin + paclitaxel maintenance therapy with niraparib

  • Arm B: 6  cycles carboplatin + paclitaxel maintenance therapy with niraparib

You will be randomly allocated to one of the treatment groups on a 1:1 ratio.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicity or withdrawal of consent.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.